Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: Endocrine diseases are common among men living with HIV (MLWH) known as curable etiology of depression.
Depression impedes adherence to treatment and perceived quality of life.
Aim: The objective of this study was to evaluate depression after medical treatment of underlying endocrine diseases among Iranian
MLWH.
Materials & Methods: We recruited a convenient sample of 296 MLWH at a referral HIV clinic from April 2013 to March 2014. In
phase I (cross-sectional evaluation), all patients were interviewed using the beck depression inventory (BDI- II) questionnaire. In
phase II, participants with moderate to severe depression (n=110, scores �21) were evaluated for endocrine diseases (evaluations:
total testosterone, triiodothyronine, thyroxine, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone
and serum cortisol). 11 patients diagnosed with hypogonadism were finally considered for hormone replacement therapy. We reevaluated
changes in depressive symptoms with BDI-II.
Results: From 237 participants, 136 (75%) had BDI scores �21; 110 participated in the endocrine evaluations. Secondary hypogonadism
(total testosterone �2.8 nmol/l; LH, FSH: normal) was the only observed abnormality in 10% (n=11) of the patients and hormone
replacement was prescribed to seven of them for three months. All patients were re-evaluated for depression; significant changes were
observed in final scores (p=0.027).
Conclusions: Evaluation and treatment of hypogonadism can help clinicians to reduce or control depression among people living
with HIV; hence improving treatment compliance and patient outcomes.
Biography
Fereshteh Ghiasvand is an Assistant Professor of Infectious Diseases department at Tehran University of Medical Sciences.